Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial

SERAPHIN was a double-blind, placebo-controlled, event-driven phase III trial that evaluated the effects of long-term treatment with macitentan, an oral endothelin receptor antagonist, in patients with pulmonary arterial hypertension (PAH). The majority of patients were receiving PAH therapy at enro...

Descripción completa

Detalles Bibliográficos
Autores principales: Jansa, Pavel, Pulido, Tomás
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5772137/
https://www.ncbi.nlm.nih.gov/pubmed/29280064
http://dx.doi.org/10.1007/s40256-017-0260-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5772137/
https://www.ncbi.nlm.nih.gov/pubmed/29280064
http://dx.doi.org/10.1007/s40256-017-0260-1

Ejemplares similares